Cipla Medpro, Serum Institute team up to provide vaccines in South Africa
09 Oct 2015
1
Cipla Medpro (Pty) Ltd, the South African subsidiary of Cipla Ltd, has entered into an exclusive agreement with the world's largest vaccine manufacturer, Serum Institute of India (SII) in South Africa, in order to facilitate reliable supply of affordable and accessible vaccines for South Africans.
The partnership will not only enable affordable and accessible vaccines for South Africans, but will also facilitate a reliable supply stream to the South African government, a Cipla release stated.
''This agreement will enable Cipla Medpro to become a significant player in the market. With a presence in 140 countries and 1.3 billion doses manufactured and sold, SII is an ideal ally for Cipla Medpro and this partnership will be instrumental in addressing the national vaccine shortage,'' Paul Miller, CEO of Cipla Medpro, South Africa, said.
SII manufactures a variety of vaccine classes, including vaccines for Polio, Diphtheria, Tetanus, BCG (Tuberculosis), Hepatitis B, Measles, Mumps and Rubella; South Africa will be participating in the majority of these portfolios.
''This Cipla Medpro-SII agreement reflects again the complementarities of our two like-minded companies in bringing high quality, affordable vaccines to more countries,'' Michel Baijot, head of vaccines, Cipla Ltd, said.
The agreement stipulates that Cipla Medpro will become the holder of all Medical Control Council (MCC) regulatory approvals such as product registrations and marketing authorisations. Cipla Medpro has exclusivity and first right of refusal of the SII pipeline within South Africa.
''SII is looking to extend the strong partnership it has with Cipla in Europe and India by working with Cipla Medpro in South Africa,'' Adar Poonawalla, CEO and executive director, SII, said.
''We are confident that this agreement will support the Department of Health in rolling out its expanded immunisation programme. Cipla Medpro will continuously look to partner with organisations that are aligned with the company's ethos of advancing healthcare for all,'' concluded Miller.
The partnership will not only enable affordable and accessible vaccines for South Africans, but will also facilitate a reliable supply stream to the South African government, a Cipla release stated.
''This agreement will enable Cipla Medpro to become a significant player in the market. With a presence in 140 countries and 1.3 billion doses manufactured and sold, SII is an ideal ally for Cipla Medpro and this partnership will be instrumental in addressing the national vaccine shortage,'' Paul Miller, CEO of Cipla Medpro, South Africa, said.
SII manufactures a variety of vaccine classes, including vaccines for Polio, Diphtheria, Tetanus, BCG (Tuberculosis), Hepatitis B, Measles, Mumps and Rubella; South Africa will be participating in the majority of these portfolios.
''This Cipla Medpro-SII agreement reflects again the complementarities of our two like-minded companies in bringing high quality, affordable vaccines to more countries,'' Michel Baijot, head of vaccines, Cipla Ltd, said.
The agreement stipulates that Cipla Medpro will become the holder of all Medical Control Council (MCC) regulatory approvals such as product registrations and marketing authorisations. Cipla Medpro has exclusivity and first right of refusal of the SII pipeline within South Africa.
''SII is looking to extend the strong partnership it has with Cipla in Europe and India by working with Cipla Medpro in South Africa,'' Adar Poonawalla, CEO and executive director, SII, said.
''We are confident that this agreement will support the Department of Health in rolling out its expanded immunisation programme. Cipla Medpro will continuously look to partner with organisations that are aligned with the company's ethos of advancing healthcare for all,'' concluded Miller.
